<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Pediatr Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">J Pediatr Neurosci</journal-id><journal-id journal-id-type="publisher-id">JPN</journal-id><journal-title-group><journal-title>Journal of Pediatric Neurosciences</journal-title></journal-title-group><issn pub-type="ppub">1817-1745</issn><issn pub-type="epub">1998-3948</issn><publisher><publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23559999</article-id><article-id pub-id-type="pmc">3611901</article-id><article-id pub-id-type="publisher-id">JPN-7-171</article-id><article-id pub-id-type="doi">10.4103/1817-1745.106470</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effective dose of topiramate in pediatric migraine prophylaxis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Abbaskhanian</surname><given-names>Ali</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Sadeghi</surname><given-names>Hamid Reza</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Erfani</surname><given-names>Ali</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Rezai</surname><given-names>Mohammad Sadegh</given-names></name><xref ref-type="aff" rid="aff2">1</xref><xref ref-type="corresp" rid="cor1"></xref></contrib></contrib-group><aff id="aff1">Department of Pediatrics, Booali Sina Hospital, Sari, Iran</aff><aff id="aff2"><label>1</label>Pediatric Infectious Disease Subspecialist, Mazandaran University of Medical Sciences, Sari, Iran</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Asst. Prof. Mohammad Sadegh Rezai, Pediatric Infectious Disease Subspecialist, Mazandaran University of Medical Sciences, Sari, Iran. E-mail: <email xlink:href="drmsrezaii@yahoo.com">drmsrezaii@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Sep-Dec</season><year>2012</year></pub-date><volume>7</volume><issue>3</issue><fpage>171</fpage><lpage>174</lpage><permissions><copyright-statement>Copyright: © Journal of Pediatric Neurosciences</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title><offsets xml_i="3110" xml_f="3120" txt_i="11" txt_f="21">Objective:</offsets></title><p><offsets xml_i="3131" xml_f="3528" txt_i="22" txt_f="419">Migraine is a common neurological disorder in childhood and adolescence. Topiramate is a new anticonvulsant drug, recently being used in migraine prophylaxis in adults, although it is not approved by the Food and Drug Administration for prevention of pediatric migraine. The present study was planned and performed to evaluate the efficacy of low-dose topiramate in pediatric migraine prophylaxis.</offsets></p></sec><sec id="st2"><title><offsets xml_i="3559" xml_f="3581" txt_i="421" txt_f="443">Materials and Methods:</offsets></title><p><offsets xml_i="3592" xml_f="3917" txt_i="444" txt_f="763">A prospective study, including 60 patients with migraine headaches was performed for a period of two months. The patients were randomly divided into two treatment groups – treated by topiramate &lt; 2 mg/kg/day and &gt; 2 mg/kg/day. All the patients were evaluated at 0, 4, and 8 weeks of the study for the clinical response.</offsets></p></sec><sec id="st3"><title><offsets xml_i="3948" xml_f="3956" txt_i="765" txt_f="773">Results:</offsets></title><p><offsets xml_i="3967" xml_f="4613" txt_i="774" txt_f="1414">The patients receiving topiramate &lt; 2 mg/kg/day (mean dose of 1.2 ± 0.7 mg/kg/day) showed a reduction in the mean (±SD) of migraine frequency from 6.2 (±2.4) to 3.0 (±1.8) episodes per month, headache intensity from 7.2 (±1.95) to 3.7 (±1.8) based on the Visual Analog Scale, and headache duration from 5.4 (±2.1) to 2.2 (±1.3) h. In the patients treated with topiramate &gt; 2 mg/kg/day (mean dose of 2.4 ± 0.5 mg/kg/day), the mean (±SD) of monthly headache frequency reduced from 6.9 (±2.1) to 3.24 (±1.2) per month, intensity from 7.11 (±1.4) to 3.14 (±2.41), and headache duration from 5.2 (±2.4) to 1.8 (±1.2) h, at the end of follow-up (</offsets><italic><offsets xml_i="4621" xml_f="4622" txt_i="1414" txt_f="1415">P</offsets></italic><offsets xml_i="4631" xml_f="4775" txt_i="1415" txt_f="1556"> &gt; 0.05). The most common side effects of topiramate were paresthesias (five patients), anorexia (four patients), drowsiness (four patients).</offsets></p></sec><sec id="st4"><title><offsets xml_i="4806" xml_f="4817" txt_i="1558" txt_f="1569">Conclusion:</offsets></title><p><offsets xml_i="4828" xml_f="5027" txt_i="1570" txt_f="1766">The results of this study demonstrated that low-dose of topiramate (&lt;2 mg/kg/day) is effective, well-tolerated, safe, and suggested as an alternative prophylactic treatment for pediatric migraine.</offsets></p></sec></abstract><kwd-group><kwd>Pediatric migraine</kwd><kwd>prophylaxis</kwd><kwd>topiramate</kwd></kwd-group></article-meta></front><body><sec id="sec1-1"><title><offsets xml_i="5196" xml_f="5208" txt_i="1775" txt_f="1787">Introduction</offsets></title><p><offsets xml_i="5219" xml_f="5512" txt_i="1788" txt_f="2081">Migraine is a common neurological disorder in childhood and adolescence. It has a prevalence of 5% in children aged 7-10 years and of 17% in adolescents. There is an equal prevalence in girls and boys prior to puberty; however, after puberty, the prevalence is 2-3 times more common in girls.[</offsets><xref ref-type="bibr" rid="ref1"><offsets xml_i="5545" xml_f="5546" txt_i="2081" txt_f="2082">1</offsets></xref><xref ref-type="bibr" rid="ref2"><offsets xml_i="5586" xml_f="5587" txt_i="2082" txt_f="2083">2</offsets></xref><offsets xml_i="5594" xml_f="5869" txt_i="2083" txt_f="2358">] Management of pediatric migraine includes lifestyle changes (in order to avoid foods, habits or environmental factors that may trigger a migraine attack), the use of abortive medications, and preventive measures, which can be either non-pharmacological or pharmacological.[</offsets><xref ref-type="bibr" rid="ref3"><offsets xml_i="5902" xml_f="5903" txt_i="2358" txt_f="2359">3</offsets></xref><xref ref-type="bibr" rid="ref4"><offsets xml_i="5943" xml_f="5944" txt_i="2359" txt_f="2360">4</offsets></xref><offsets xml_i="5951" xml_f="6127" txt_i="2360" txt_f="2536">] Topiramate has been shown to be effective for migraine prevention in adults. Limited data is available for the efficacy and safety of topiramate in the pediatric population.[</offsets><xref ref-type="bibr" rid="ref5"><offsets xml_i="6160" xml_f="6161" txt_i="2536" txt_f="2537">5</offsets></xref><offsets xml_i="6168" xml_f="6216" txt_i="2537" txt_f="2585">] The exact mechanism of topiramate is unknown.[</offsets><xref ref-type="bibr" rid="ref6"><offsets xml_i="6249" xml_f="6250" txt_i="2585" txt_f="2586">6</offsets></xref><offsets xml_i="6257" xml_f="6535" txt_i="2586" txt_f="2864">] It is proposed that epilepsy and migraine share some of the same pathophysiological mechanisms, including abnormal function of voltage-gated sodium and calcium channels, reduced gamma-aminobutyric acid (GABA) -mediated inhibition, and increased glutamate-mediated excitation.[</offsets><xref ref-type="bibr" rid="ref7"><offsets xml_i="6568" xml_f="6569" txt_i="2864" txt_f="2865">7</offsets></xref><xref ref-type="bibr" rid="ref8"><offsets xml_i="6609" xml_f="6610" txt_i="2865" txt_f="2866">8</offsets></xref><offsets xml_i="6617" xml_f="6618" txt_i="2866" txt_f="2867">]</offsets></p><p><offsets xml_i="6625" xml_f="6824" txt_i="2868" txt_f="3067">Few uncontrolled studies done to evaluate the efficacy of topiramate in migraine prophylaxis especially in refractory causes confirmed that it could be effective in prophylaxis of migraine headache.[</offsets><xref ref-type="bibr" rid="ref5"><offsets xml_i="6857" xml_f="6858" txt_i="3067" txt_f="3068">5</offsets></xref><xref ref-type="bibr" rid="ref9"><offsets xml_i="6898" xml_f="6899" txt_i="3068" txt_f="3069">9</offsets></xref><offsets xml_i="6906" xml_f="7150" txt_i="3069" txt_f="3313">] Data to support the effectiveness, tolerability, and adequate dosage of pediatric topiramate are not well-reported. The present study was planned and performed to evaluate the efficacy of low-dose topiramate in pediatric migraine prophylaxis.</offsets></p></sec><sec sec-type="materials|methods" id="sec1-2"><title><offsets xml_i="7213" xml_f="7234" txt_i="3315" txt_f="3336">Materials and Methods</offsets></title><p><offsets xml_i="7245" xml_f="7638" txt_i="3337" txt_f="3730">The study was designed as a prospective study and was performed in 60 children (between 5 and 15 years of age) treated with topiramate for prevention of migraine headaches, at a pediatric neurology clinic in north of Iran from March 2011 through September of 2011. The diagnosis of migraine was based on 2005 definition by the International Headache Society which included childhood criteria.[</offsets><xref ref-type="bibr" rid="ref10"><offsets xml_i="7672" xml_f="7674" txt_i="3730" txt_f="3732">10</offsets></xref><offsets xml_i="7681" xml_f="7682" txt_i="3732" txt_f="3733">]</offsets></p><p><offsets xml_i="7689" xml_f="7996" txt_i="3734" txt_f="4041">A general evaluation and physical examination were performed in the first visit, and patients were asked baseline laboratory screening tests and a migraine checklist, including demographic and clinical details of the patients such as frequency, duration, and intensity of headache was filed for each person.</offsets></p><p><offsets xml_i="8003" xml_f="8038" txt_i="4042" txt_f="4077">Exclusion criteria were as follows:</offsets></p><p><offsets xml_i="8045" xml_f="8046" txt_i="4078" txt_f="4079">
</offsets><list list-type="order"><list-item><p><offsets xml_i="8084" xml_f="8159" txt_i="4079" txt_f="4154">Prior or current prophylactic treatment for migraine in the last two months</offsets></p></list-item><list-item><p><offsets xml_i="8189" xml_f="8219" txt_i="4155" txt_f="4185">Persistent increasing headache</offsets></p></list-item><list-item><p><offsets xml_i="8249" xml_f="8290" txt_i="4186" txt_f="4227">Change of behavior and school performance</offsets></p></list-item><list-item><p><offsets xml_i="8320" xml_f="8386" txt_i="4228" txt_f="4294">Abnormal neurologic and persistent focal signs (e.g., papilledema)</offsets></p></list-item><list-item><p><offsets xml_i="8416" xml_f="8478" txt_i="4295" txt_f="4357">Neuroimaging studies indicative of a focal neurological lesion</offsets></p></list-item><list-item><p><offsets xml_i="8508" xml_f="8570" txt_i="4358" txt_f="4420">Contraindications for topiramate (e.g., glaucoma, renal stone)</offsets></p></list-item><list-item><p><offsets xml_i="8600" xml_f="8637" txt_i="4421" txt_f="4458">Patients with known case of epilepsy.</offsets></p></list-item></list><offsets xml_i="8660" xml_f="8661" txt_i="4459" txt_f="4460">
</offsets></p><p><offsets xml_i="8668" xml_f="8939" txt_i="4461" txt_f="4732">After simple randomized dividing the patients into two groups, topiramate was started at a dose of greater or lower than 2 mg/kg/day. For the clinical assessment of the patients, to minimize the potential side effects, the dose was slowly increased 0.5 mg/kg/day in the 2</offsets><sup><offsets xml_i="8944" xml_f="8946" txt_i="4732" txt_f="4734">nd</offsets></sup><offsets xml_i="8952" xml_f="10153" txt_i="4734" txt_f="5935"> week, divided into two daily doses according to patient′s response and tolerance. There were three stages of this study such as at the beginning of study (Base-line), period which was 4-weeks after receiving drugs (phase I) and at the end of 8-weeks after receiving drugs (phase II). Headache severity was scored on a 1-3 point scale with one presenting no effect on daily activity, two for partial inhibition of daily activity and three for loss of daily activities based on the Visual Analog Scale (VAS). The response to topiramate treatment was recorded according to the patients and parents′ reports during follow-up visits, and was defined as: Complete cessation of headache attacks (excellent response), reduction of headache frequency more than 50% of baseline (good response), reduction of headache frequency less than 50% of baseline (fair response), No response or increase of headache attacks (poor response). The data analysis were performed by statistical package for social sciences version 13. We analyzed number of headaches per month, changes in Body Mass Index (BMI) and dosage before and after treatment according to the presence or absence of adverse effects, using the Student′s </offsets><italic><offsets xml_i="10161" xml_f="10162" txt_i="5935" txt_f="5936">t</offsets></italic><offsets xml_i="10171" xml_f="10279" txt_i="5936" txt_f="6044"> test. The incidence of migraine attacks and adverse effects before and after treatment was analyzed using χ</offsets><sup><offsets xml_i="10284" xml_f="10285" txt_i="6044" txt_f="6045">2</offsets></sup><offsets xml_i="10291" xml_f="10352" txt_i="6045" txt_f="6106"> nonparametric test. Results are expressed as mean (±SD) and </offsets><italic><offsets xml_i="10360" xml_f="10361" txt_i="6106" txt_f="6107">P</offsets></italic><offsets xml_i="10370" xml_f="10425" txt_i="6107" txt_f="6159"> &lt; 0.05 was considered as statistically significant.</offsets></p><p><offsets xml_i="10432" xml_f="10858" txt_i="6160" txt_f="6586">Before starting the study all the patients were given extensive information on the study nature and methods, and we obtained an informed written consent, and patients were advised that they could withdraw from the study at any stage for any reason. This study was performed in accordance with the declaration of Helsinki and subsequent revision and approved by the Ethics committee at Mazandaran University of Medical Science.</offsets></p></sec><sec sec-type="results" id="sec1-3"><title><offsets xml_i="10911" xml_f="10918" txt_i="6588" txt_f="6595">Results</offsets></title><p><offsets xml_i="10929" xml_f="11372" txt_i="6596" txt_f="7039">Sixty patients who met the inclusion criteria were enrolled in the study. Five of the patients were excluded due to no follow-up, patient′s choice or drug intolerance. Ultimately, out of 55 patients who completed the course of study, 30 (54.5%) were girls, and 25 (45.5%) were boys. The mean age was 8 years (range: 6.3-14.5 years). Patients in the two groups were not significantly different regarding age, gender, and other characteristics (</offsets><italic><offsets xml_i="11380" xml_f="11381" txt_i="7039" txt_f="7040">P</offsets></italic><offsets xml_i="11390" xml_f="11961" txt_i="7040" txt_f="7602"> &gt; 0.05). Mean (±SD) numbers of monthly headache frequency at the beginning of the study with topiramate in two groups receiving &gt; 2 mg/kg/day and &lt; 2 mg/kg/day were 6.9 (±2.1) and 6.2 (±2.4), and mean (±SD) duration of each episode of headache at the baseline were 5.2 (±2.4), and 5.4 (±2.1) h, respectively. The mean (±SD) headache intensity at the beginning of the trial was 7.11 (±1.4) and 7.2 (±1.9) and the base line data show that there were no statistically significant differences between the two groups according to base line headache characteristics (</offsets><italic><offsets xml_i="11969" xml_f="11970" txt_i="7602" txt_f="7603">P</offsets></italic><offsets xml_i="11979" xml_f="12100" txt_i="7603" txt_f="7721"> &gt; 0.05). Data about comparison of headache parameters at baseline and after 4 and 8 weeks of treatment are recorded [</offsets><xref ref-type="table" rid="T1"><offsets xml_i="12132" xml_f="12139" txt_i="7721" txt_f="7728">Table 1</offsets></xref><offsets xml_i="12146" xml_f="12331" txt_i="7728" txt_f="7913">]. Frequency intensity and duration of migraine headache decreased significantly between repeated follow-up visits of each patient in the study according to statistical analysis tests [</offsets><xref ref-type="table" rid="T2"><offsets xml_i="12363" xml_f="12370" txt_i="7913" txt_f="7920">Table 2</offsets></xref><offsets xml_i="12377" xml_f="12612" txt_i="7920" txt_f="8155">]. Clinical response was quantified as excellent in 61%, good in 19%, and fair in 13%, with no response in 7% of the patients. Topiramate was well tolerated. No significant reduction in BMI or weight loss occurred during the treatment.</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="12660" xml_f="12667" txt_i="8156" txt_f="8163">Table 1</offsets></label><caption><p><offsets xml_i="12687" xml_f="12779" txt_i="8163" txt_f="8255">Comparison of headache parameters at baseline and after 4 and 8 weeks of beginning the study</offsets></p></caption><graphic xlink:href="JPN-7-171-g001"></graphic></table-wrap><table-wrap id="T2" position="float"><label><offsets xml_i="12897" xml_f="12904" txt_i="8256" txt_f="8263">Table 2</offsets></label><caption><p><offsets xml_i="12924" xml_f="13038" txt_i="8263" txt_f="8377">Comparison of mean reduction of intensity, frequency, and duration of headache in group after 8 weeks of treatment</offsets></p></caption><graphic xlink:href="JPN-7-171-g002"></graphic></table-wrap><p><offsets xml_i="13115" xml_f="13250" txt_i="8378" txt_f="8513">The most common side effects of topiramate were paresthesias (five patients), anorexia (four patients), and drowsiness (four patients).</offsets></p></sec><sec sec-type="discussion" id="sec1-4"><title><offsets xml_i="13306" xml_f="13316" txt_i="8515" txt_f="8525">Discussion</offsets></title><p><offsets xml_i="13327" xml_f="13416" txt_i="8526" txt_f="8615">Migraine prevalence estimates vary from 1% to 3% at 7 years and 4% to 11% at 7-15 years.[</offsets><xref ref-type="bibr" rid="ref11"><offsets xml_i="13450" xml_f="13452" txt_i="8615" txt_f="8617">11</offsets></xref><offsets xml_i="13459" xml_f="13460" txt_i="8617" txt_f="8618">–</offsets><xref ref-type="bibr" rid="ref13"><offsets xml_i="13494" xml_f="13496" txt_i="8618" txt_f="8620">13</offsets></xref><offsets xml_i="13503" xml_f="13564" txt_i="8620" txt_f="8681">] Many children with migraines require prophylactic therapy.[</offsets><xref ref-type="bibr" rid="ref14"><offsets xml_i="13598" xml_f="13600" txt_i="8681" txt_f="8683">14</offsets></xref><offsets xml_i="13607" xml_f="13752" txt_i="8683" txt_f="8828">] The successful treatment of pediatric migraine includes an individually tailored regimen of both non pharmacologic and pharmacologic measures.[</offsets><xref ref-type="bibr" rid="ref15"><offsets xml_i="13786" xml_f="13788" txt_i="8828" txt_f="8830">15</offsets></xref><offsets xml_i="13795" xml_f="14063" txt_i="8830" txt_f="9098">] Non-pharmacologic therapies such as abiding by appropriate sleep patterns, diet, stress reduction and exercise may be helpful in preventing headaches. If the patient can identify triggers, such as particular foods or caffeine, avoidance is recommended, if possible.[</offsets><xref ref-type="bibr" rid="ref14"><offsets xml_i="14097" xml_f="14099" txt_i="9098" txt_f="9100">14</offsets></xref><offsets xml_i="14106" xml_f="14280" txt_i="9100" txt_f="9274">] Many treatments are currently used for migraine prophylaxis, including β-blockers, calcium channel antagonists, serotonin antagonists, antidepressants and anti-epileptics.[</offsets><xref ref-type="bibr" rid="ref16"><offsets xml_i="14314" xml_f="14316" txt_i="9274" txt_f="9276">16</offsets></xref><xref ref-type="bibr" rid="ref17"><offsets xml_i="14357" xml_f="14359" txt_i="9276" txt_f="9278">17</offsets></xref><offsets xml_i="14366" xml_f="14485" txt_i="9278" txt_f="9397">] Topiramate is an antiepileptic drug with established efficacy and safety in older children and adults with epilepsy.[</offsets><xref ref-type="bibr" rid="ref16"><offsets xml_i="14519" xml_f="14521" txt_i="9397" txt_f="9399">16</offsets></xref><xref ref-type="bibr" rid="ref17"><offsets xml_i="14562" xml_f="14564" txt_i="9399" txt_f="9401">17</offsets></xref><offsets xml_i="14571" xml_f="14619" txt_i="9401" txt_f="9449">] Although, before its approval in August 2004.[</offsets><xref ref-type="bibr" rid="ref18"><offsets xml_i="14653" xml_f="14655" txt_i="9449" txt_f="9451">18</offsets></xref><xref ref-type="bibr" rid="ref19"><offsets xml_i="14696" xml_f="14698" txt_i="9451" txt_f="9453">19</offsets></xref><offsets xml_i="14705" xml_f="15370" txt_i="9453" txt_f="10115">] Topiramate has been demonstrated to be helpful in adults, few studies have been conducted to establish evaluating topiramate′s efficacy, safety, optimal dose, length of treatment, and side effects in childhood migraine. So this present study was designed and performed to compare different dosage of topiramate in pediatric migraine prophylaxis. In our study, the mean dose in patients receiving topiramate (&lt;2 mg/kg/day) was 1.2 ± 0.7 mg/kg/day. (Range: 0.5-2 mg/kg/day) comparing with 2.4 ± 0.5 mg/kg/day in group receiving more than 2 mg/kg/day. The mean dose of topiramate used in several studies varied from 1.7 ± 1 mg/kg/day S.D. to 3.5 ± 1.7 mg/kg/day.[</offsets><xref ref-type="bibr" rid="ref5"><offsets xml_i="15403" xml_f="15404" txt_i="10115" txt_f="10116">5</offsets></xref><xref ref-type="bibr" rid="ref9"><offsets xml_i="15444" xml_f="15445" txt_i="10116" txt_f="10117">9</offsets></xref><xref ref-type="bibr" rid="ref20"><offsets xml_i="15486" xml_f="15488" txt_i="10117" txt_f="10119">20</offsets></xref><offsets xml_i="15495" xml_f="15513" txt_i="10119" txt_f="10137">] However, Winner </offsets><italic><offsets xml_i="15521" xml_f="15526" txt_i="10137" txt_f="10142">et al</offsets></italic><offsets xml_i="15535" xml_f="15537" txt_i="10142" txt_f="10144">.[</offsets><xref ref-type="bibr" rid="ref20"><offsets xml_i="15571" xml_f="15573" txt_i="10144" txt_f="10146">20</offsets></xref><offsets xml_i="15580" xml_f="15716" txt_i="10146" txt_f="10282">] suggested that possibly topiramate at dose of 50 mg/day, administered prophylactically, may reduce migraines in adolescents but Lewis </offsets><italic><offsets xml_i="15724" xml_f="15729" txt_i="10282" txt_f="10287">et al</offsets></italic><offsets xml_i="15738" xml_f="15740" txt_i="10287" txt_f="10289">.[</offsets><xref ref-type="bibr" rid="ref21"><offsets xml_i="15774" xml_f="15776" txt_i="10289" txt_f="10291">21</offsets></xref><offsets xml_i="15783" xml_f="16110" txt_i="10291" txt_f="10618">] evaluated the efficacy and safety of topiramate for migraine prevention in pediatric subjects aged 12-17 years. They found that topiramate at 100 mg/day, but not 50 mg/day, resulted in a statistically significant reduction in the monthly migraine attack rate from baseline versus placebo (median, 72.2% vs. 44.4%). Campistol </offsets><italic><offsets xml_i="16118" xml_f="16123" txt_i="10618" txt_f="10623">et al</offsets></italic><offsets xml_i="16132" xml_f="16134" txt_i="10623" txt_f="10625">.[</offsets><xref ref-type="bibr" rid="ref22"><offsets xml_i="16168" xml_f="16170" txt_i="10625" txt_f="10627">22</offsets></xref><offsets xml_i="16177" xml_f="16451" txt_i="10627" txt_f="10895">] presented that effective mean dose of topiramate in pediatric migraine prophylaxis is 3.5 ± 1.7 mg/kg/day. The results of this study show that though both groups had (&lt;2 mg/kg/day vs. &gt;2 mg/kg/day) decreased monthly headache frequency, intensity and duration. Borzy </offsets><italic><offsets xml_i="16459" xml_f="16464" txt_i="10895" txt_f="10900">et al</offsets></italic><offsets xml_i="16473" xml_f="16475" txt_i="10900" txt_f="10902">.[</offsets><xref ref-type="bibr" rid="ref23"><offsets xml_i="16509" xml_f="16511" txt_i="10902" txt_f="10904">23</offsets></xref><offsets xml_i="16518" xml_f="16828" txt_i="10904" txt_f="11214">] studied a group of 21 children aged 6-18 years who were diagnosed with chronic daily headaches and treated with topiramate. In this report 62% of families reported that low-dose topiramate (average dose of 30 mg/day) was successful in reducing both the frequency and severity of headache episodes. Campistol </offsets><italic><offsets xml_i="16836" xml_f="16841" txt_i="11214" txt_f="11219">et al</offsets></italic><offsets xml_i="16850" xml_f="16852" txt_i="11219" txt_f="11221">.[</offsets><xref ref-type="bibr" rid="ref22"><offsets xml_i="16886" xml_f="16888" txt_i="11221" txt_f="11223">22</offsets></xref><offsets xml_i="16895" xml_f="17215" txt_i="11223" txt_f="11543">] presented 24 children treated with topiramate for 4 months. And recorded a reduction in migraine frequency but this was not significantly different from baseline and significant differences in migraine severity and duration of the episodes. Our study revealed that 61% children had an excellent or good response. Cruz </offsets><italic><offsets xml_i="17223" xml_f="17228" txt_i="11543" txt_f="11548">et al</offsets></italic><offsets xml_i="17237" xml_f="17239" txt_i="11548" txt_f="11550">.[</offsets><xref ref-type="bibr" rid="ref9"><offsets xml_i="17272" xml_f="17273" txt_i="11550" txt_f="11551">9</offsets></xref><offsets xml_i="17280" xml_f="17705" txt_i="11551" txt_f="11967">] reported that 28 (76%) of children with migraine had an excellent or good response to topiramate. Topiramate was well tolerated and adverse effects occurred in 13 (23.6%) of the patients (five with parenthesis, four with drowsiness, and four with anorexia). Patients taking &gt; 2 mg/kg/day were more likely to exhibit side effects: Eight of 13 were taking &gt; 2 mg/kg/day, compared with children taking &lt; 2 mg/kg/day (</offsets><italic><offsets xml_i="17713" xml_f="17714" txt_i="11967" txt_f="11968">P</offsets></italic><offsets xml_i="17723" xml_f="17973" txt_i="11968" txt_f="12218">= 0.042). There was a direct relationship between dosage and side effects. Another study, evaluating the safety, and tolerability of topiramate show that the most common side effects were paresthesia, weight loss, sleepiness, and worsened headaches.[</offsets><xref ref-type="bibr" rid="ref21"><offsets xml_i="18007" xml_f="18009" txt_i="12218" txt_f="12220">21</offsets></xref><xref ref-type="bibr" rid="ref24"><offsets xml_i="18050" xml_f="18052" txt_i="12220" txt_f="12222">24</offsets></xref><offsets xml_i="18059" xml_f="18674" txt_i="12222" txt_f="12834">] This study has several limitations. First, it was conducted at a single center with a smaller subject group. Another important fact that questionnaire were recalled from the patient′s or parent′s memory. Furthermore, larger, prospective studies are required to evaluate the long-term efficacy, tolerability, optimal dose, length of treatment, and long-term effects of topiramate in this population. In conclusion, the results of this study demonstrated that low-dose of topiramate (&lt;2 mg/kg/day) is effective, well-tolerated, safe, and suggested as an alternative prophylactic treatment for pediatric migraine.</offsets></p></sec></body><back><ack><p>The authors kindly thank the Mazandaran University of Medical Science for financial support.</p></ack><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil.</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>N</given-names></name><name><surname>Millman</surname><given-names>G</given-names></name><name><surname>James</surname><given-names>E</given-names></name></person-group><article-title>Migraine headache in children</article-title><source>Clin Evid</source><year>2006</year><volume>15</volume><fpage>469</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">16973019</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ottman</surname><given-names>R</given-names></name><name><surname>Hong</surname><given-names>S</given-names></name><name><surname>Lipton</surname><given-names>RB</given-names></name></person-group><article-title>Validity of family history data on severe headache and migraine</article-title><source>Neurology</source><year>1993</year><volume>43</volume><fpage>1954</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">8413952</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hershey</surname><given-names>AD</given-names></name><name><surname>Winner</surname><given-names>PK</given-names></name></person-group><article-title>Pediatric migraine: Recognition and treatment</article-title><source>J Am Osteopath Assoc</source><year>2005</year><volume>105</volume><fpage>2S</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15928347</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>DW</given-names></name><name><surname>Scott</surname><given-names>D</given-names></name><name><surname>Rendin</surname><given-names>V</given-names></name></person-group><article-title>Treatment of pediatric headache</article-title><source>Expert Opin Pharmacother</source><year>2002</year><volume>3</volume><fpage>1433</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">12387689</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winner</surname><given-names>P</given-names></name></person-group><article-title>Overview of pediatric headache</article-title><source>Curr Treat Options Neurol</source><year>2004</year><volume>6</volume><fpage>471</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">15461925</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginger</surname><given-names>CM</given-names></name><name><surname>April</surname><given-names>MD</given-names></name><name><surname>Brandon</surname><given-names>PB</given-names></name><name><surname>Bryan</surname><given-names>LL</given-names></name></person-group><article-title>Topiramate: Safety and efficacy of its use in the prevention and treatment of migraine</article-title><source>J Cent Nerv Syst Dis</source><year>2011</year><volume>3</volume><fpage>155</fpage><lpage>68</lpage></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietrobon</surname><given-names>D</given-names></name></person-group><article-title>Migraine: New molecular mechanisms</article-title><source>Neuroscientist</source><year>2005</year><volume>11</volume><fpage>373</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">16061523</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faught</surname><given-names>E</given-names></name></person-group><article-title>Efficacy of topiramate as adjunctive therapy in refractory partial seizures: United States trial experience</article-title><source>Epilepsia</source><year>1997</year><volume>38</volume><fpage>S24</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9092954</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruz</surname><given-names>MJ</given-names></name><name><surname>Valencia</surname><given-names>I</given-names></name><name><surname>Legido</surname><given-names>A</given-names></name><name><surname>Kothare</surname><given-names>SV</given-names></name><name><surname>Khurana</surname><given-names>DS</given-names></name><name><surname>Yum</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Efficacy and tolerability of topiramate in pediatric migraine</article-title><source>Pediatr Neurol</source><year>2009</year><volume>41</volume><fpage>167</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">19664530</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olesen</surname><given-names>J</given-names></name></person-group><article-title>The international classification of headache disorders</article-title><source>Rev Neurol (Paris)</source><year>2005</year><volume>161</volume><fpage>689</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">16141961</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bille</surname><given-names>BS</given-names></name></person-group><article-title>Migraine in school children. A study of the incidence and short term prognosis, and a clinical, psychological and encephalographic comparison between children with migraine and matched control</article-title><source>Acta Paediatr Suppl</source><year>1962</year><volume>51</volume><fpage>1</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">13869189</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sillanpaa</surname><given-names>M</given-names></name></person-group><article-title>Prevalence of migraine and other headache in finnish children starting scho</article-title><source>Headache</source><year>1976</year><volume>15</volume><fpage>288</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">1245411</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mortimer</surname><given-names>MJ</given-names></name><name><surname>Kay</surname><given-names>J</given-names></name><name><surname>Jaron</surname><given-names>A</given-names></name></person-group><article-title>Epidemiology of headache and childhood. Migraine in an urban general practice using ad hoc, valquist and IHS criteria</article-title><source>Dev Med Child Neurol</source><year>1992</year><volume>34</volume><fpage>1095</fpage><lpage>992</lpage><pub-id pub-id-type="pmid">1451940</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eiland</surname><given-names>LS</given-names></name></person-group><article-title>Anticonvulsant use for prophylaxis of the pediatric migraine</article-title><source>J Pediatr Health Care</source><year>2007</year><volume>21</volume><fpage>392</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">17980806</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>D</given-names></name><name><surname>Diamond</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>V</given-names></name></person-group><article-title>Prophylactic treatment of pediatric migraine</article-title><source>Headache</source><year>2004</year><volume>44</volume><fpage>230</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15012660</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>French</surname><given-names>JA</given-names></name><name><surname>Kanner</surname><given-names>AM</given-names></name><name><surname>Bautista</surname><given-names>J</given-names></name><name><surname>Abou-Khalil</surname><given-names>B</given-names></name><name><surname>Browne</surname><given-names>T</given-names></name><name><surname>Harden</surname><given-names>CL</given-names></name><etal></etal></person-group><article-title>Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society</article-title><source>Neurology</source><year>2004</year><volume>62</volume><fpage>1261</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">15111660</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valencia</surname><given-names>I</given-names></name><name><surname>Fons</surname><given-names>C</given-names></name><name><surname>Kothare</surname><given-names>SV</given-names></name><name><surname>Khurana</surname><given-names>DS</given-names></name><name><surname>Yum</surname><given-names>S</given-names></name><name><surname>Hardison</surname><given-names>HH</given-names></name><etal></etal></person-group><article-title>Efficacy and tolerability of topiramate in children younger than 2 years old</article-title><source>J Child Neurol</source><year>2005</year><volume>20</volume><fpage>667</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16225812</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silberstein</surname><given-names>SD</given-names></name><name><surname>Neto</surname><given-names>W</given-names></name><name><surname>Schmitt</surname><given-names>J</given-names></name><name><surname>Jacobs</surname><given-names>D</given-names></name></person-group><article-title>Topiramate in migraine prevention: Results of a large controlled trial</article-title><source>Arch Neurol</source><year>2004</year><volume>61</volume><fpage>490</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15096395</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Von Seggern</surname><given-names>RL</given-names></name><name><surname>Mannix</surname><given-names>LK</given-names></name><name><surname>Adelman</surname><given-names>JU</given-names></name></person-group><article-title>Efficacy of topiramate in migraine prophylaxis: A retrospective chart analysis</article-title><source>Headache</source><year>2002</year><volume>42</volume><fpage>804</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12390645</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winner</surname><given-names>P</given-names></name><name><surname>Gendolla</surname><given-names>A</given-names></name><name><surname>Stayer</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Yuen</surname><given-names>E</given-names></name><name><surname>Battisti</surname><given-names>WP</given-names></name><etal></etal></person-group><article-title>Topiramate for migraine prevention in adolescents: A pooled analysis of efficacy and safety</article-title><source>Headache</source><year>2006</year><volume>46</volume><fpage>1503</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">17115983</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>D</given-names></name><name><surname>Winner</surname><given-names>P</given-names></name><name><surname>Saper</surname><given-names>J</given-names></name><name><surname>Ness</surname><given-names>S</given-names></name><name><surname>Polverejan</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12-17 years of age</article-title><source>Pediatrics</source><year>2009</year><volume>123</volume><fpage>924</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">19255022</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campistol</surname><given-names>J</given-names></name><name><surname>Campos</surname><given-names>J</given-names></name><name><surname>Casas</surname><given-names>C</given-names></name><name><surname>Herranz</surname><given-names>JL</given-names></name></person-group><article-title>Topiramate in the prophylactic treatment of migraine in children</article-title><source>J Child Neurol</source><year>2005</year><volume>20</volume><fpage>251</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">15832623</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borzy</surname><given-names>JC</given-names></name><name><surname>Koch</surname><given-names>TK</given-names></name><name><surname>Schimschock</surname><given-names>JR</given-names></name></person-group><article-title>Effectiveness of topiramate in the treatment of pediatric chronic daily headache</article-title><source>Pediatr Neurol</source><year>2005</year><volume>33</volume><fpage>314</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16243217</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietrobon</surname><given-names>D</given-names></name></person-group><article-title>Migraine: New molecular mechanisms</article-title><source>Neuroscientist</source><year>2005</year><volume>4</volume><fpage>373</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">16061523</pub-id></element-citation></ref></ref-list></back></article>